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The trillions of microbial symbionts normally hosted by mammals have important influences on the develop-
ment and function of the immune system. We highlight recently discovered cellular and molecular mecha-
nisms by which they impact autoimmune diseases—in particular, gut-distal disorders. Besides provoking
a reconsideration of the definition of immunological ‘‘self’’ and ‘‘nonself,’’ these new findings evoke exciting
possibilities for the discovery of a whole new class of immunomodulatory molecules.Introduction
The principal function of the immune system is to defend the
body from pathogenic invasion—by microbes from without and
tumors from within. Both the rapidity of the innate and diversity
of the adaptive immune systems are mobilized to this end. An
unavoidable byproduct of generation of the needed diversity is
that T and B lymphocytes capable of recognizing self-constitu-
ents occasionally arise in the primary lymphoid organs—the
thymus and bone marrow, respectively. A complex network of
immunological tolerance mechanisms has evolved to cull these
self-reactive specificities from the emerging lymphocyte reper-
toire or to keep them in check if they somehow manage to exit
to the periphery. But occasionally one or more of these mecha-
nisms goes awry, resulting in a state of autoimmunity, which
sometimes progresses to a pathological condition, autoimmune
disease.
Immunological tolerance, autoimmunity, and autoimmune
disease have been elements of immunologists’ vocabulary for
decades—and hundreds of experiments and debates have
been aimed at their elucidation. Nonetheless, recent advances
in our understanding of the composition and activities of micro-
bial populations that colonize diverse body sites as commensals,
mutualists, or parasites prompt a reconsideration, or at least
extension, of some basic concepts. Here we will touch on how
postmodern appreciation of the universe of microbes hosted
by mammals modifies our definition of self:nonself, how sym-
biont microbiota impact development of the immune system,
how they can influence the initiation or outcome of autoimmu-
nity, and how we might translate emerging knowledge on micro-
biota and microbiomes to the human context.
Nonself or Self?
Mammals are sterile at birth, the neonate acquiring itsmicrobiota
during and shortly after naissance. In adults, symbiont commu-
nities can fluctuate with alterations in host diet or physiology;
however, they are stable enough over time that kinship relations
can be discerned (Ley et al., 2008; Turnbaugh et al., 2009). The
relative importance of host environment versus genetics in
shaping the composition remains under debate. Certainly,
phylogenetic influences are discernable (Ley et al., 2008), and
a given species appears to have a ‘‘core microbiome’’ at the
gene level (Turnbaugh et al., 2009; Benson et al., 2010). Yet
monozygotic and dizygotic twin pairs have a similar degree of
variability in gut microbial communities (Turnbaugh et al.,2009). In any case, the composition of the microbiota reflects
eons of host symbiont coevolution—with fine tuning of both
host and microbe genomes—and variability may be an evolu-
tionary advantage in and of itself.
These observations put a new slant on issues related to immu-
nological tolerance and autoimmunity. If an adult mammal
harbors over ten times more bacterial cells in the intestinal tract
than there are somatic and germ cells in its entire body, where
does ‘‘self’’ end and ‘‘nonself’’ begin? Is the microbiome to
be considered an environmental factor (because it responds
to surrounding conditions) or an epigenetic factor (because it
passes from generation to generation)? It seems appropriate to
encompass the core microbiota in the definition of a mammal’s
‘‘self,’’ and to consider that tolerance mechanisms that evolved
to eschew attack on the tissues will be shared with those em-
ployed to maintain a balance with the universe of symbionts.
It Takes Two to Tango.
One of the major impacts of the mammalian microbiota is its
effect on the development and function of the immune system.
In fact, communities of bacterial and immune cells are closely
linked, especially those residing in the intestinal tract, each influ-
encing and being influenced by the other (reviewed in Lee and
Mazmanian [2010] and Littman and Pamer [this issue, pp. 311–
323]). While the means by which the immune system deals
with microbes is an old and ongoing preoccupation of immunol-
ogists, just how the symbiont microbiota shapes immunity
has become amenable to precise mechanistic dissection only
relatively recently, reflecting advances both in high-throughput
sequencing methods and in our knowledge of lymphocyte
subpopulations.
In general terms, the incomplete state of the immune system
in adult germ-free (GF) and neonatal individuals argues that
microbes drive its maturation. Reported defects include both
gut-associated and systemic abnormalities: defective T, B, and
innate cell compartments in mucosal tissue, fewer CD4+ T
lymphocytes in all peripheral lymphoid organs, a systemic tilt
to the T-helper (Th) 2 phenotype, and reduced complements of
IgG and IgA antibodies (Abs). All of these aberrancies are
reversed within weeks after microbial colonization.
In more specific terms, gut-resident microbes—sometimes
even a single species—can have a striking influence on the emer-
gence and/or stability of particular CD4+ T cell subsets. For
example, segmented filamentous bacteria (SFB), a gut-residentCell Host & Microbe 10, October 20, 2011 ª2011 Elsevier Inc. 297
Table 1. Mouse Models OF Autoimmune Disease
Human disease Mouse Model Reference
Primary Immunological
Mechanism(s)
Effect of Introducing
Microbiota
Inflammatory
arthritis
Il1rn/ (knockout
mouse line)
(Abdollahi-Roodsaz
et al, 2008)
Emphasizes innate immune
system: cytokines, Toll-like
receptors.
Full complement (GF vs. SPF):
enhanced disease. lactobacillus
bifidus: enhanced disease
K/BxN (T cell receptor
transgenic mouse line)
(Wu et al, 2010) T, B, and innate immune
cells important. Highlights
role of autoAbs.
Full complement (GF vs. SPF):
enhanced disease. SFB:
enhanced disease
Collagen-induced
arthritis (rat)
(Breban et al, 1993) T, B, and innate immune cells
important. Adjuvant-induced.
Full complement (GF vs. SPF):
dampened disease
SKG (mouse line with
a point mutation in Zap70)
(Yoshitomi et al, 2005;
Hashimoto et al, 2010)
T-cell-mediated. Defective
central tolerance of T cells.
Full complement (SPF vs. C):
enhanced disease. Fungal
b-glucans: enhanced disease
Multiple Sclerosis Experimental autoimmune
encephalomyelitis
(EAE) (mouse)
(Lee et al, 2010) T-cell-mediated, though
multiple other cell-types play
a role. Adjuvant-induced.
Full complement (GF vs. SPF):
enhanced disease. SFB:
enhanced disease
Autoimmune
polyglandular
syndrome
Aire/ (knockout
mouse line)
(Gray et al, 2007) T-cell-mediated. Defective
central tolerance of T cells.
Full complement (GF vs. SPF):
no effect
Type-1 diabetes Nonobese diabetic (NOD)
(genetically selected
inbred mouse strain)
(King and Sarvetnick, 2011;
Kriegel et al, 2011)
T-cell-mediated, though
multiple other immune cells
impact. Multigenic.
Full complement (GF vs SPF):
varies in different colonies. SFB:
protects females
Only those studies referred to in the text are presented. GF = germ-free; SPF = specific-pathogen-free; C = conventionally housed.
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related to Clostridia (Kuwahara et al., 2011, Sczesnak et al.,
2011,Prakashetal., 2011), promotes thedevelopmentofa robust
Th17 population in the small-intestinal (SI) lamina propria (LP) of
mice (Gaboriau-Routhiau et al., 2009; Ivanov et al., 2009);
a defined mix of Clostridia strains induces a population of
Foxp3+CD4+ regulatory T (Treg) cells in the murine large-intes-
tinal (LI) LP (Atarashi et al., 2011); and the human gut symbiont
Bacteroides fragilis exerts multiple effects on CD4+ effector and
regulatory T cell populations when it colonizes mice (Mazmanian
et al., 2005; Mazmanian et al., 2008; Round and Mazmanian,
2010; Round et al., 2011). The pathways from microbe coloniza-
tion to immune cell modulation are so far only poorly defined but
have been suggested to include the following: an action of serum
amyloid A (SAA) on dendritic cells (DCs) (Ivanov et al., 2009),
ATP-mediated activation of DCs (Atarashi et al., 2008), the induc-
tion of TGF-b expression by gut epithelial cells (Atarashi et al.,
2011), an effect of B. fragilis polysaccharide A (PSA) on DCs
(Mazmanian et al., 2005), and an interaction between B. fragilis
PSA and Treg TLR-2 (Round et al., 2011). Whether or not all of
these proposed mechanisms will survive close scrutiny, the
perception is that we have only scratched the surface so far
and thatmicrobes have likely evolvedmanymeans tomanipulate
mammalian immune systems.
Transcending the Neighborhood.
Given the multifaceted interplay between the mammalian micro-
biota and immune system, it is not surprising that alterations in
symbiont microbe communities were long ago linked to immune
pathologies, notably allergic and autoimmune disorders (Stra-
chan, 1989; Wills-Karp et al., 2001). Ties to inflammatory bowel
diseases are easy to envisage; as these are being reviewed by
Littman and Pamer (in this issue), we will not deal with them298 Cell Host & Microbe 10, October 20, 2011 ª2011 Elsevier Inc.here. A number of associations between the microbiota (or
defined elements of it) and particular gut-distal autoimmune
disorders have been reported over the years, but it is only quite
recently that techniques that permit one to probe the cellular and
molecular underpinnings of such correlations became available.
Comparisons of disease parameters in different autoimmune
models (detailed in Table 1) housed under GF versus specific-
pathogen-free (SPF) or conventional conditions have shown
the full gamut of responses to loss of the microbiota: disease
amelioration (e.g., Abdollahi-Roodsaz et al., 2008; Wu et al.,
2010; Lee et al., 2011), no significant effect (Gray et al., 2007),
or disease exacerbation (Breban et al., 1993). It may seem per-
plexing that the microbiota can have opposing impacts on the
development of autoimmune disease—more so when there are
divergent outcomes with models of purportedly the same
disorder, e.g., arthritis (Abdollahi-Roodsaz et al., 2008; Wu
et al., 2010; Breban et al., 1993), or even with the same model
in the hands of different investigators, e.g., NOD mice (Kriegel
et al., 2011; King and Sarvetnick, 2011). These ‘‘discrepancies’’
are likely to clear up with more precise knowledge of colonizing
microbiota at different animal facilities and more profound
appreciation for the heterogeneity of the pathogenic mecha-
nisms underlying the various models.
Recent findings on the impact of SFB on autoimmune mani-
festations in different mouse models serve to illustrate this last
point. Mice kept under GF conditions have few Th17 cells,
notably in the major site of their accumulation, the SI-LP; recolo-
nization of GF mice with intestinal microbiota induces a robust
Th17 compartment within days (Ivanov et al., 2008). Strikingly,
monocolonization with SFB, a filamentous bacterium intimately
associated with the intestinal epithelium, can produce the
same result (Gaboriau-Routhiau et al., 2009; Ivanov et al.,
2009). The implication of Th17 cells and/or IL-17 in a number
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influence of SFB in rodent disease models. Arthritis was greatly
attenuated in the K/BxNmodel (Table 1) when housed GF (vis-a`-
vis SPF); robust disease was restored 10–14 days after introduc-
tion of GF mice into an SPF facility, and within days of SFB
monocolonization (Wu et al., 2010). The sequence of events
was documented to be as so: SFB colonization/ development
of an SI-LP Th17 compartment/ appearance of Th17 cells in
the spleen, likely via migration from the gut / generation of
arthritogenic B cells and autoAbs in the spleen, promoted by
a direct impact of IL-17A on B cells / autoAb deposition in
the joints, ultimately provoking arthritis by well-established
mechanisms entailing the mobilization of inflammatory cells
and cytokines. This scenario is consistent with the fact that treat-
ment of K/BxNmice with anti-IL-17 mAb blocked the production
of autoAbs and the consequent development of arthritis (Wu
et al., 2010). Next, parallel results on an experimental autoim-
mune encephalomyelitis (EAE) model of multiple sclerosis (MS)
were reported: EAE was attenuated in GF mice, associated
with a reduction in Th17 cells (also fewer Th1 and more Treg
cells); monocolonization with SFB induced EAE, subtended by
an increased Th17 compartment in both the gut and spinal
cord (Lee et al., 2011). The consistency in the results on the
arthritis and EAE models served to increase the surprise when
it was found that SFB was associated with disease protection
in NOD mice, a spontaneous model of type-1 diabetes (T1D)
(Kriegel et al., 2011). Individuals from the same NOD colony
differed in their SFB status, which was reflected in their relative
susceptibility to disease: while almost all females that were
free of this microbe developed T1D, only about 15% that
harbored it got diabetes. Proof of SFB’s role in disease protec-
tion, in particular whether it is a direct one or mediated through
cosymbionts, must await monocolonization or cohousing exper-
iments. In the meantime, the only difference found in the immune
systems of SFB+ and SFB female NOD mice was a greatly
reduced SI-LP Th17 population in the latter.
How might SFB promote autoimmune disease in one context
and dampen it in another? It is important to keep in mind that
not all autoimmune disorders have the same mechanisms of
initiation, propagation, and regulation. Just as it was too naive
in the 1990s to think that autoimmune manifestations univer-
sally reflect a Th1/Th2 imbalance, it is an oversimplification
today to expect that they always signal an upset in the Th17/
Treg balance. Indeed, considering the models discussed
above, most murine arthritis models have a strong Th17 depen-
dency; there is still active debate over the relative importance
of Th1 and Th17 cells in EAE; and there is little, and contradic-
tory, support for a critical role for Th17 (over Th1) cells in NOD
diabetes (discussed in Kriegel et al. [2011]). Th subsets are
known to crossinhibit, so it follows that a Th17-inducing
microbe (like SFB) can potentially inhibit a Th1-dependent
disease (like NOD diabetes). An alternative possibility is that
another SFB activity might have differential impact in different
autoimmune contexts. For example, SFB induces IL-22 expres-
sion, as well (Ivanov et al., 2009; Kriegel et al., 2011), and this
cytokine’s ability to repair intestinal epithelium might counter
breaches of the intestinal barrier thought to promote T1D (Lee
et al., 2010; Turley et al., 2005) but not known to impact arthritis
or EAE.Such pleiotropic effects are also characteristic of the human
intestinal symbiont, B. fragilis. This microbe and its product,
PSA, dampened mouse models of colitis and EAE, mobilizing
mechanisms ranging from inhibition of Th1 cells, to induction
of IL-10-producing CD4+ cells, to reduction of the Th-17 com-
partment, to enhancement of Treg activity (Mazmanian et al.,
2005, 2008; Round and Mazmanian, 2010; Round et al., 2011).
What ties these mechanisms together? One possibility is that
different processes come into play according to the modality
(B. fragilis versus PSA), route, or dose of administration, or in
different contexts of autoimmunity. A perhaps more satisfying
explanation is that Tregs are the lead players, secondarily damp-
ening Th17 or Th1 or even Ab effector responses, depending on
the context. This interpretation would be consistent with the
recent suggestion that PSA might signal Tregs directly through
TLR-2, which in turn restrain Th17 cells (Round et al., 2011).
However, this scenario would need to accommodate the current
concept that distinct subsets of Tregs have evolved to regulate
different Th subsets (Campbell and Koch, 2011).
Lastly, additional complexity derives from the fact that
different microbes can impact the same immune system com-
partments, by similar or dissimilar mechanisms. For example,
arthritis in the SKG mouse model (Table 1) is more severe in
a colony housed under conventional than under SPF conditions;
disease exacerbation in the dirtier facility was attributed to fungal
colonization, which, through a b-glucan/Dectin-1 interaction,
induced arthritogenic Th17 cells in a complement-dependent
manner (Hashimoto et al., 2010; Yoshitomi et al., 2005). And
arthritis in the il-1rn/ model can be provoked by monocoloni-
zation of GF mice with Lactobacillus bifidus, through a TLR-4/
Il-1/Th17 axis (Abdollahi-Roodsaz et al., 2008).
All in all, then, this seems like a very fruitful, but exceptionally
complicated, area of investigation, reflecting the stunning
complexity of both the microbiota and the immune system,
and the myriad planes of interaction between them. Almost
certainly, systems approaches will be helpful in elucidating
important principles that govern host:symbiont interplay as it
impacts autoimmune disease. Just as certainly, reductionist
strategies, such as examination of monocolonized and gene-
manipulated mice, will continue to unravel key processes, path-
ways, and players. Another line of investigation in its early days is
genetic dissection. Genome-wide analysis of a cross between
C57Bl/6 mice and an ICR-derived outbred line revealed loci
that were associated with individual microbial species, others
linked to groups of related taxa, and still others with pleiotropic
impacts on groups of distinctly related organisms (Benson
et al., 2010). Of even greater interest in the context of autoim-
mune disease is a report that the MHC/HLA-like molecule
Cd1d could regulate the composition of mouse intestinal
communities (Nieuwenhuis et al., 2009). Might long-recognized
but little-understood MHC/HLA associations with a variety of
autoimmune disorders at least in part reflect influences on
symbiont microbe colonization? On a related note, it might be
worthwhile to extend the concept of molecular mimicry, as
a trigger of autoimmunity, to the symbiont microbiome. Indeed,
a recent study identified amicrobial peptide, common tomultiple
classes of symbionts, that had weak sequence homology with
myelin basic protein and could induce disease in a humanized
mouse model of multiple sclerosis (Harkiolaki et al., 2009).Cell Host & Microbe 10, October 20, 2011 ª2011 Elsevier Inc. 299
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Of course, the end goal is to translate this new knowledge,
mostly derived from rodent models, to a better understanding
of autoimmune diseases in humans. Most such disorders show
a 30%–70% discordance rate in identical twins, leaving plenty
of room for environmental, epigenetic, and stochastic elements
to play a role. Certainly, genetics cannot explain the discon-
certing increase in a number of immune maladies over the past
several decades, notably T1D, MS, and asthma (particularly in
so-called ‘‘developed’’ nations). Hence the proposal and later
modification of the ‘‘hygiene hypothesis’’—changing diets,
improved sanitary conditions, increased use of antibiotics, etc.
prevent the immune system from being adequately ‘‘primed’’
during its maturation, resulting in Th subset imbalances, Treg
cell deficiencies, and other faults that predispose to immune
diseases. It is easy to envisage how the microbiota fits into
such a scheme—it is modified in response to diet, sanitation,
and antibiotics, and its composition instructs immune-system
maturation.
Unraveling the microbiome/immune-system/autoimmune-
disease axis in humans will be difficult and complex. Micro-
biome-wide association studies are currently in progress but
are likely to be subject to several of the same weaknesses and
disappointments as genome-wide association studies (GWAS)
are—and then some, given that, while an individual’s genome
is constant, its microbiome fluctuates over time, with the envi-
ronment, with drug treatment, etc. Stem-cell technology should
aid in the development of culture systems that capture the inter-
actions between microbial, immune-system, and intestinal cells,
but these are likely to be challenging endeavors that require
maintaining a three-dimensional structure, optimally under
anaerobic conditions. No doubt, rodent models, in particular
humanized-mouse models, will continue to elucidate critical
principles. Murine and human immune systems are much
more similar than they are different; the species’ microbiota
share dominant groupings, but there are many divergences at
the lower taxonomy levels; though there may be greater simi-
larity in the microbiomes (Ley et al., 2008). Encouragingly,
human-specific commensals like B. fragilis can colonize the
mouse intestine, impact the immune system, and modulate
autoimmune and inflammatory diseases (Mazmanian et al.,
2005, 2008).
Regardless of the impediments, studies on the microbiota
and microbiome open new vistas on autoimmunity and autoim-
mune disease. There may or may not prove to be associations
between particular symbionts and particular autoimmune dis-
orders. And their identification may or may not yield novel
approaches to prevention or treatment – entailing administra-
tion of prebiotics, probiotics or drugs. But even independent of
such associations, the microbiome promises to be a treasure-
trove of novel immunomodulatory molecules. It has coevolved
with its host for eons, developing a multitude of strategies to
tame the immune system. We should learn, and heed, its
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